Stem-cell derived pancreatic endoderm cells in the treatment of T1DM

Finding a way to safely replace the destroyed β-cells of patients with type 1 diabetes mellitus (T1DM) has long been a research goal in the T1DM field. Now, two papers report preliminary findings from an ongoing phase I/II trial in which patients with T1DM received implants of stem-cell derived pancreatic endoderm cells within an encapsulation device named PEC-Direct.

Categories: Stem Cells therapy


contract research organization

stem cell therapy